Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Basic Research

Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer

Prostate Cancer and Prostatic Diseases volume 15, pages 346–352 (2012)Cite this article

Subjects

Abstract

Background:

Prostate cancer incidence and mortality vary dramatically by geographical location. Both are higher in developed countries. Some attribute this to westernized lifestyles of high-energy diets and limited physical activity with consequent obesity. Obesity and obesity-related diseases like diabetes cause hyperinsulinaemia, which upregulates pro-survival cell signalling. Previous work revealed diet-induced hyperinsulinaemia enhances prostate cancer xenograft growth in vivo. Metformin, an antidiabetic medication, reduces hyperinsulinaemia and also exhibits antineoplastic properties. Herein, we assess the potential additive benefit of combining bicalutamide antiandrogen therapy with metformin, in vitro and in vivo.

Methods:

Using clonogenic assays, we assessed the effect of bicalutamide and/or metformin on clonogenicity in prostate cancer cell lines. Western blot and cell cycle analyses were used to elucidate mechanisms of interaction between the drugs in androgen receptor (AR)-positive (LNCaP) and AR-negative (PC3) cell lines. The combination treatment regimen was assessed in vivo using an LNCaP murine xenograft model.

Results:

Micromolar bicalutamide or millimolar metformin caused a significant dose-dependent reduction in clonogenicity (P<0.001). Combination treatment further significantly reduced clonogenicity (P<0.005) with greater effects in AR-positive cells. Western blot and cell cycle analyses suggested differing mechanisms of interaction in AR-positive and -negative cell lines. Following combination treatment, LNCaP cells exhibited an altered cell proliferation (decreased phospho mammalian target of rapamycin expression) and perturbed cell cycle kinetics (G1/S cell cycle arrest). PC3 cells showed evidence of enhanced apoptosis (increased Bcl-2-associated X protein and decreased total caspase 3 expression). Markedly diminished tumour growth occurred following combination treatment in vivo (P<0.001).

Conclusions:

Combining bicalutamide and metformin significantly reduces prostate cancer cell growth further than either monotherapy. In AR-positive cells, this effect appeared to be mediated by reducing proliferation rates, whereas in AR-negative cells the combination treatment appeared to promote apoptosis. This combination drug regimen may improve prostate-cancer-specific survival by the direct antineoplastic properties outlined.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. American Cancer Society. Cancer Facts and Figures 2010. American Cancer Society: Atlanta, 2010.

  2. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM . Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006; 295: 1549–1555.

    Article  CAS  Google Scholar 

  3. IARC. International Agency for Research in Cancer. Weight Control and Physical Activity. IARC press: Lyon, 2002.

  4. MacInnis RJ, English DR, Haydon AM, Hooper JL, Gertig DM, Giles GG . Body size and composition and risk of rectal cancer (Australia). Cancer Causes Control 2006; 17: 1291–1297.

    Article  Google Scholar 

  5. Freedland SJ, Platz EA, Presti Jr JC, Aronson WJ, Amling CL, Kane CJ et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 2006; 175: 500–504.

    Article  Google Scholar 

  6. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1977–1983.

    Article  Google Scholar 

  7. Littman AJ, White E, Kristal AR . Anthropometrics and prostate cancer risk. Am J Epidemiol 2007; 165: 1271–1279.

    Article  Google Scholar 

  8. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109: 675–684.

    Article  Google Scholar 

  9. Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R et al. Association of diet-induced hyperinsulinaemia with accelerated of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 2007; 99: 1793–1800.

    Article  Google Scholar 

  10. Feller S, Boering H, Pischon T . Body mass index, waist circumference, and the risk of type 2 diabetes mellitus. Dtsch Arztebl Int 2010; 107: 470–476.

    PubMed  PubMed Central  Google Scholar 

  11. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH . The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88–107.

    Article  Google Scholar 

  12. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D’Agostino RB . Trends in the incidence of type 2 diabetes mellitus from the 1970 to the 1990s. The Framingham Heart Study. Circulation 2006; 113: 2914–2918.

    Article  Google Scholar 

  13. Cusi K, Consoli A, DeFronza RA . Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4059–4067.

    CAS  PubMed  Google Scholar 

  14. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063–2069.

    Article  CAS  Google Scholar 

  15. Kahn B, Alquier T, Carling D, Hardie DG . AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15–25.

    Article  CAS  Google Scholar 

  16. Sahra IB, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576–3586.

    Article  Google Scholar 

  17. Zakikhani M, Dowling R, Fabtus IG, Sonenberg N, Pollak M . Metformin is an AMP kinase–dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269–10273.

    Article  CAS  Google Scholar 

  18. Zhuang Y, Mikimins WK . Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, regulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 2008; 3: 18–29.

    Article  Google Scholar 

  19. Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M . Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr-Relat Cancer 2008; 15: 833–839.

    Article  CAS  Google Scholar 

  20. Zakikhani M, Dowling RJO, Sonenberg N, Pollak M . The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Rev 2008; 15: 369–375.

    Article  Google Scholar 

  21. Gotlieb WH, Samuet J, Beuchamp M-C, Gu J, Lau S, Pollak MN et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008; 110: 246–250.

    Article  CAS  Google Scholar 

  22. Cantrell LA, Zhou C, Mendivil A, Molloy KM, Gehrig PA, Bae-Jump VL . Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol 2010; 116: 92–98.

    Article  CAS  Google Scholar 

  23. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 1999; 91: 1869–1876.

    Article  CAS  Google Scholar 

  24. Knudsen KE, Arden KC, Cavenee WK . Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem 1998; 273: 20213–20222.

    Article  CAS  Google Scholar 

  25. McCrohan AM, Morrissey C, O’Keane, Mulligan N, Watson C, Smith J et al. Effects of the dual 5-alpha reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. Cancer 2006; 106: 2743–2752.

    Article  CAS  Google Scholar 

  26. Abramoff MD, Magelhaes PJ, Ram SJ . Image processing with ImageJ. Biophotonics International 2004; 11: 36–42.

    Google Scholar 

  27. Frid A, Sterner G, Londahl M, Wiklander C, Cato A, Vinge E et al. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function. Diabetes Care 2010; 33: 1291–1293.

    Article  CAS  Google Scholar 

  28. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 2007; 64: 1290–1302.

    Article  CAS  Google Scholar 

  29. Floyd MS, Teahan SJ, Fitzpatrick JM, Watson RW . Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines. Prostate Cancer Prostatic Dis 2009; 12: 25–33.

    Article  Google Scholar 

  30. Hou M, Venier N, Sugar L, Musquera M, Pollak M, Kiss A et al. Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. Biochem Biophys Res Commun 2010; 397: 537–542.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors gratefully acknowledge Prostate Cancer Canada and the Canadian Institute for Health Research to Dr Venkateswaran for generously funding this body of work.

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    A J Colquhoun, N A Venier, A D Vandersluis, R Besla, L H Klotz & V Venkateswaran

  2. Department of Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    L M Sugar

  3. Department of Research Design and Biostatistics, Institute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    A Kiss

  4. Division of Urology, Department of Surgery, Princess Margaret Hospital, Toronto, ON, Canada

    N E Fleshner

  5. Department of Medicine and Oncology, McGill University, Montreal, QC, Canada

    M Pollak

Authors
  1. A J Colquhoun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N A Venier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A D Vandersluis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Besla
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L M Sugar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Kiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N E Fleshner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Pollak
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L H Klotz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. V Venkateswaran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V Venkateswaran.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Colquhoun, A., Venier, N., Vandersluis, A. et al. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis 15, 346–352 (2012). https://doi.org/10.1038/pcan.2012.16

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2012.16

Keywords

This article is cited by

Search

Advanced search

Quick links